Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1241-1260 of 2,120 trials

Facial Lines: IPN10200 Treatment Study

We are studying a new treatment for adults with moderate to severe upper facial lines to see if it improves their appearance compared to a placebo. The trial will assess both safety and effectiveness of the treatment.

Frown Lines6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Squamous Cell Carcinoma of the Penis: Lymphadenectomy and Chemotherapy Study

We are studying a treatment combining surgery and chemotherapy for patients with inguinal lymph node metastases. The goal is to see if this approach improves survival and reduces the chance of cancer returning.

Penis Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Cangrelor and Bivalirudin

We are studying a new combination of medications for patients with heart attacks in critical condition. The goal is to see if this treatment can prevent blood clots while keeping bleeding risks low.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Lutetium Lu 177 Edotreotide for Pediatric Tumors

We are studying a new targeted therapy for children with somatostatin receptor-positive tumors to find the right dose and evaluate its safety. This trial will also look at how well the treatment works compared to standard care.

RhabdomyosarcomaLymphomaNeuroendocrine Tumor>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyPediatrics

Diffuse Large B-Cell Lymphoma: Axicabtagene Ciloleucel Study

We are studying a new treatment for patients with late relapse of diffuse large B-cell lymphoma to see if it improves their condition and quality of life. The trial also looks at the safety of this treatment.

Recurrent B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Prostate Cancer Diagnosis: 18F-PSMA PET/MRI Study

We are testing a new imaging method to see how well it identifies clinically significant prostate cancer. This may help improve diagnosis accuracy for patients.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyUrology

Vulvar Squamous Cell Carcinoma: Pembrolizumab Study

We are studying whether Pembrolizumab can help shrink tumors in patients with vulvar squamous cell carcinoma before surgery. This trial also looks at how the treatment affects the immune system.

Vulvar Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

IgG4-Related Disease: Abatacept Treatment Study

We are investigating whether abatacept can help reduce the risk of disease recurrence in people with IgG4-related disease. This study aims to provide insights into a new treatment option for managing this condition.

IgG4-Related Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Generalized Myasthenia Gravis: DNTH103 Treatment Study

We are testing a new treatment called DNTH103 for adults with generalized myasthenia gravis. The study aims to evaluate its safety, tolerability, and effectiveness in managing symptoms.

Myasthenia Gravis3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Kidney Health: CO2 Injection in Vascular Procedures

We are testing a new method using Carbon Dioxide instead of traditional contrast media for patients at risk of kidney injury during vascular interventions. This study aims to see if it can help prevent serious kidney problems after the procedure.

Peripheral Arterial Disease (PAD)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNephrology

Shingrix Vaccine: Safety in Psoriasis and Psoriatic Arthritis

We are studying the safety and immune response of the Shingrix vaccine in patients with psoriasis or psoriatic arthritis. Our goal is to see how the vaccine affects disease activity and to monitor any side effects.

Psoriatic ArthritisPsoriasis Vulgaris>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Cirrhosis Due to NASH/MASH: Efruxifermin Study

We are testing a new medication, Efruxifermin, for people with compensated cirrhosis from NASH/MASH. The study aims to see if it improves liver health and reduces related health risks compared to a placebo.

Non-Alcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementEndocrinologyHepatology

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Acute Heart Failure: Intra-Abdominal Pressure and Ultrasound Study

We are exploring whether using intra-abdominal pressure and ultrasound can improve diuretic treatment for patients with acute heart failure. This study aims to see if these methods help reduce congestion and improve recovery compared to standard treatment.

Acute Heart Failure>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Episodic Migraine: MEDI0618 Treatment Study

We are investigating whether the new medication MEDI0618 can help reduce the number of migraine days for adults with episodic migraines compared to a placebo. This study aims to assess its safety and effectiveness.

Migraine6-12 monthsEfficacy phase (II)Investigational MedicinesNeurology

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: Elacestrant and Everolimus Study

We are studying a combination of elacestrant and everolimus for patients with advanced breast cancer that has specific mutations. The goal is to see if this treatment helps delay cancer progression compared to a placebo.

Advanced Estrogen Receptor-Positive Breast Cancer1-2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyOncology

Sepsis Treatment: New Antibiotic Dosing Strategy

We are testing a new way to dose beta-lactam antibiotics for critically ill patients with sepsis. The goal is to see if this improves their recovery in the ICU.

Sepsis1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Lung Cancer: Sacituzumab and Zimberelimab Treatment

We are studying a combination of two medications for patients with non-small cell lung cancer who have had surgery but are not disease-free. The goal is to see if this treatment can help prevent cancer from returning.

Resectable Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPulmonology